6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation
Key Takeaways
- OECD 451 two-year rodent bioassays typically use at least 50 animals/sex/group, both sexes, at least three dose levels plus concurrent control, and about 24 months (18 months may suit some mouse strains).
- ICH S1A/S1B/S1C frame when a bioassay is needed, how to test (including the 2022 S1B(R1) weight-of-evidence path that may conclude a 2-year rat study adds no value), and how to pick the high dose (MTD, 25-fold rodent:human AUC, or 1500 mg/kg/day limit when human dose is ≤500 mg/day and rodent exposure is at least ~10-fold).
- The 6-month rasH2-Tg mouse study is an accepted alternative to a 2-year mouse bioassay; S1B(R1) uses a 50-fold AUC criterion for high-dose selection in rasH2 rather than the 25-fold used in 2-year conventional rodents.
- Peto analysis treats incidental tumors with a prevalence method and fatal tumors with a death-rate method; misclassifying cause of death biases both tests. Historical controls inform rare tumors and drift, but concurrent controls remain primary.
- Hyperplasia is increased cell number with retained architecture; neoplasia is autonomous growth with architectural disruption. Integrate tumor data with the genotoxicity battery and mode of action before calling a human carcinogen.
Why bioassays are interpreted, not merely counted
A two-year rodent study can produce statistically increased tumors that are not human-relevant, and it can miss a signal if the high dose never stressed the animal or if early deaths removed the population at risk. DABT items in this area test whether you can read design, survival, tumor context, and mechanism together. OpenExamPrep independent study material covers OECD 451, the ICH S1 family, U.S. protocol concurrence, and neoplastic evaluation. It does not claim official approval, review, or partnership with OECD, ICH, FDA, or ABT.
OECD 451 design and conduct
The objective is to observe animals for a major portion of their lifespan for neoplastic lesions during or after exposure. Rats and mice, both sexes, are the usual species. Each dose group and the concurrent control should contain at least 50 animals per sex. Use at least three dose levels plus concurrent control. Duration is normally 24 months for rodents; 18 months may be more appropriate for some mouse strains. Consider terminating when survivors in lower-dose or control groups fall below about 25%. Daily observations, body weight, food consumption, full necropsy, and extensive histopathology are required.
Survival is part of validity. If the high dose kills most animals in month 6, you have a poorly designed toxicity study, not a sensitive cancer bioassay: animals that die early cannot express late-arising tumors, and Peto fatal-tumor tests become dominated by non-tumor deaths. Palpable masses, time-to-tumor, and cause-of-death calls at necropsy are study conduct, not afterthoughts for the statistician.
Pharmaceutical programs historically used a two-species approach (rat plus mouse). Chemical programs (National Toxicology Program, OECD) also use rat and mouse two-year studies. Combined chronic/carcinogenicity designs (OECD 453) add a smaller chronic-toxicity satellite; do not confuse the 10/sex chronic satellite with the 50/sex carcinogenicity phase.
ICH S1: when, how, and how high
ICH S1A addresses when carcinogenicity studies are warranted for pharmaceuticals—generally for continuous or repeated clinical use of at least 6 months, or when there is cause for concern (genotoxicity, class effect, preneoplastic lesions). Short-term therapies may not need a bioassay.
ICH S1B addresses testing strategy. The long-standing approach was a 2-year rat plus a 2-year mouse (or a short-term transgenic mouse). The July 2022 ICH S1B(R1) addendum introduced a documented weight-of-evidence (WoE) evaluation to decide whether a 2-year rat study is likely to add value. Factors include targets and pathways with known carcinogenic association, drug metabolism and exposure, histopathology and hormonal perturbation from repeat-dose studies, genotoxicity per S2(R1), and immune modulation per S8. If WoE indicates the 2-year rat would not inform human risk, that study may be omitted; a mouse carcinogenicity assessment (2-year conventional or 6-month rasH2-Tg) generally remains. Investigative work (special stains, hormones, clinical mechanistic data) can resolve uncertainty.
U.S. sponsors still seek CDER Executive Carcinogenicity Assessment Committee (Exec CAC) protocol concurrence before starting a bioassay. FDA’s carcinogenicity study protocol submissions guidance (2002, still the operational protocol document) describes special protocol assessment, dose-selection packages, and rangefinding. The 2022 change that DABT candidates must not miss is S1B(R1), which FDA implements as ICH guidance—not a separate “rewrite of OECD 451.”
ICH S1C(R2) addresses high-dose selection for 2-year studies:
| Criterion | Practical meaning |
|---|---|
| Maximum tolerated dose (MTD) | Highest dose that does not compromise survival from effects other than tumors; modest body-weight decrement (often about 10%) is a common MTD anchor, without physiology that wrecks the study (uncontrolled hypotension, bleeding). |
| 25-fold AUC | Rodent plasma AUC at the high dose ≈ 25 times human AUC at the maximum recommended human dose; used when toxicity is low and a higher MTD would only add non-informative burden. |
| 1500 mg/kg/day limit | Appropriate when human dose is ≤500 mg/day and rodent exposure at 1500 mg/kg/day is still at least about 10-fold human exposure. If human dose exceeds 500 mg/day, the high dose may rise toward the maximum feasible dose. |
| Maximum feasible dose | For diet, often cited as about 5% of diet; for other routes, practicality and local tolerance. |
| Saturation of absorption | Further dose increases that do not raise systemic exposure are not useful. |
Using the 25-fold AUC cap when human exposure is poorly estimated, or using 1500 mg/kg/day when rodent AUC is not even 10-fold human, is a protocol error, not a 3Rs success.
Transgenic alternatives: rasH2
The rasH2-Tg mouse (CB6F1-Tg rasH2, hemizygous human c-Ha-ras) is a 26-week alternative to a conventional 2-year mouse study when accepted for the product class. Include a positive control (for example urethane or another lab-qualified positive) to show the model can respond. S1B(R1) states that the S1C(R2) high-dose criteria apply to rasH2 except that the plasma AUC ratio is 50-fold rodent:human rather than 25-fold. rasH2 does not automatically replace a 2-year rat study; S1B(R1) WoE decides the rat. Other historical transgenics (p53+/−, Tg.AC) are more indication- or route-specific and are not a generic substitute.
Peto incidental versus fatal tumors
Tumor statistics must respect context of observation (Peto et al. 1980; FDA statistical carcinogenicity guidance).
- Fatal tumors caused or contributed to death. Analyze with the death-rate method: the animal is at risk until death from that tumor.
- Incidental tumors were found at necropsy and did not kill the animal. Analyze with the prevalence method in time intervals, so groups that die early of other causes are not credited with extra “negative” time they never had at risk in the same way.
- Some tumors (for example certain skin masses) are mortality-independent and need yet another handling.
If a pathologist labels every liver tumor “fatal” because the animal died, or every tumor “incidental” because a schedule kill occurred, both tests are biased. Cause-of-death is a pathology call made animal by animal.
Historical controls from the same laboratory, strain, diet, and recent time window help interpret rare tumors and control drift (for example rising background lymphoma). They do not replace concurrent controls. A high-dose increase that sits inside a very wide historical range but is still a clear concurrent-control trend is not automatically dismissed; a single rare tumor type slightly above concurrent control may be unimpressive if historical incidence already covers it.
Hyperplasia versus neoplasia, then weight of evidence
Hyperplasia is an increase in cell number with architecture largely preserved, often still stimulus-dependent and potentially reversible if the stimulus stops. Hypertrophy is larger cells, not more cells. Neoplasia is relatively autonomous growth with architectural disruption, atypia, and, if malignant, invasion or metastasis. Many rodent liver programs show a continuum: enzyme induction and hypertrophy → hyperplasia → adenoma → carcinoma. The continuum does not make every hypertrophic liver a cancer finding; it does mean you look for progression, multiplicity, atypia, and whether the same organ shows toxicity or a rodent-specific mode of action (peroxisome proliferator-activated receptor alpha, constitutive androstane receptor, prolonged TSH drive, urinary calculi).
Integrate:
- Genotoxicity (S2(R1)). A DNA-reactive mutagen plus tumors in multiple organs is a different human-risk story than a non-genotoxic high-dose rodent liver tumor with a well-documented rodent-specific MOA.
- Mode of action and human relevance (species receptors, exposure multiples, key events).
- Tumor type and rarity, latency, and malignancy.
- Dose and exposure relative to clinical use.
Realistic scenario
A 2-year rat study used a high dose set only to 4-fold human AUC because the rangefinder showed palatable diet limitation, survival was good, and there was no MTD body-weight effect. Thyroid follicular adenomas increased at that high dose with follicular hypertrophy in 13-week data and a known liver-enzyme/TSH mechanism. Exec CAC would likely have called the high dose inadequate on S1C(R2) grounds and still asked for a TSH-based MOA package. Raising the dose toward 25-fold AUC or a true MTD, or justifying a limit dose with measured exposures, is the design fix; calling the study “negative for cancer” because 4-fold felt comfortable is not.
Traps
- Using n=10/sex from a chronic satellite as if it were the carcinogenicity group size.
- Applying the 25-fold AUC cap to rasH2 (S1B(R1) uses 50-fold).
- Ignoring cause of death when choosing Peto prevalence versus death-rate tests.
- Replacing concurrent controls with a historical-control range.
- Equating hepatocellular hypertrophy with carcinoma.
For a low-toxicity small molecule whose maximum recommended human dose is 200 mg/day, which high-dose statement matches ICH S1C(R2) for a 2-year rat bioassay?
Pathologists classify most hepatocellular adenomas as incidental (found at terminal necropsy, not the cause of death) and most malignant lymphomas as fatal. Which analysis is appropriate?
ICH S1B(R1) (2022) weight of evidence suggests a 2-year rat study would not add value for a non-genotoxic small molecule. Which statement about alternatives is correct?